Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • About half of the patients who initiate therapy with mepolizumab discontinue treatment within the first or second year. Concomitant use of short-acting β2-agonists and oral corticosteroids drops during mepolizumab use. https://bit.ly/3aRISqS.

authors

  • Lee, Jason K
  • Gendron, Alain
  • Knutson, Michelle
  • Sriskandarajah, Niroshan
  • Mbuagbaw, Lawrence
  • Noorduyn, Stephen G

publication date

  • January 2021